Interestingly, targeted CDK9 inhibitors, such as voruciclib, potently induce apoptosis through MCL-1 depletion in many hematologic cell lines and in a subset of breast cancer cell lines, and have recently entered clinical trials for the treatment of hematological malignancies (Figure 3) [61,62]. This evidence concerns the gene MCL1 and breast cancer.